https://orcid.org/0000-0002-2175-5117
References
- Austin RP, Davis AM, Manners CN. 1995. Partitioning of ionizing molecules between aqueous buffers and phospholipid vesicles. J Pharm Sci. 84(10):1180–1183.
- Beaumont V, Mrzljak L, Dijkman U, Freije R, Heins M, Rassoulpour A, Tombaugh G, Gelman S, Bradaia A, Steidl E, et al. 2016. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. Exp Neurol. 282:99–118.
- Centre for Drug Evaluation and Research and Centre for Veterinary Medicine 2001. Guidance for industry: Bioanalytical methods validation. U.S. Department of Health and Human Services FDA.
- Dutton GJ. 1980. Glucuronidation of drugs and other compounds. Boca Raton: CRC Press.
- Forrest CM, Mackay GM, Stoy N, Spiden SL, Taylor R, Stone TW, Darlington LG. 2010. Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease. J Neurochem. 112(1):112–122.
- Guidetti P, Reddy PH, Tagle DA, Schwarcz R. 2000. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Neurosci Lett. 283(3):233–235.
- Hop CE, Wang Z, Chen Q, Kwei G. 1998. Plasma-pooling methods to increase throughput for in Vivo pharmacokinetic screening. J Pharm Sci. 87(7):901–903.
- Lu Y, Shao M, Wu T. 2020. Kynurenine-3-monooxygenase: a new direction for the treatment in different diseases. Food Sci Nutr. 8(2):711–719.
- Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, Park BK. 2010. Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos. 31(7):367–395.
- Sathyasaikumar KV, Stachowski EK, Amori L, Guidetti P, Muchowski PJ, Schwarcz R. 2010. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington’s disease. J Neurochem. 113(6):1416–1425.
- Swainson LA, Ahn H, Pajanirassa P, Khetarpal V, Deleage C, Estes JD, Hunt PW, Munoz-Sanjuan I, McCune JM. 2019. Kynurenine 3-monooxygenase inhibition during acute simian immunodeficiency virus infection lowers PD-1 expression and improves Post-Combination Antiretroviral Therapy CD4+ T Cell Counts and Body Weight. J Immunol. 203(4):899–910.
- Toledo-Sherman LM, Prime ME, Mrzljak L, Beconi MG, Beresford A, Brookfield FA, Brown C, Brown J, Cardaun I, Courtney SM, et al. 2015. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease. J Med Chem. 58(3):1159–1183.